Intellia Therapeutics Announces Inducement Grants

Biopharmaceutical company issues stock awards to new employees under Nasdaq listing rule

Apr. 3, 2026 at 9:06pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a stack of legal documents, a pen, and a pair of reading glasses arranged elegantly on a clean, white seamless background, conceptually representing the legal and financial aspects of Intellia's employee inducement grants.Intellia Therapeutics' latest inducement grants underscore its efforts to build a world-class team as it advances its pioneering gene-editing therapies.Cambridge Today

Intellia Therapeutics, a leading biopharmaceutical company focused on CRISPR gene editing, announced that it has awarded inducement grants of time-based restricted stock units (RSUs) to 13 new employees. The grants, made under Intellia's 2024 Inducement Plan, are intended as a material inducement to employment at the company.

Why it matters

Intellia's announcement of these inducement grants highlights the company's continued growth and expansion of its workforce as it advances its CRISPR-based therapies. The grants, made outside of Intellia's stockholder-approved equity incentive plans, are a common practice for public companies to attract and retain top talent.

The details

The inducement grants consist of 67,150 shares of Intellia's common stock in the form of time-based RSUs. One-third of the RSUs will vest annually over a three-year period, subject to each employee's continued service at the company. These awards were approved by Intellia's compensation committee and granted in accordance with Nasdaq Listing Rule 5635(c)(4).

  • The inducement grants were awarded on April 1, 2026.

The players

Intellia Therapeutics, Inc.

A leading clinical-stage biopharmaceutical company focused on revolutionizing medicine through CRISPR gene editing and other core technologies.

Got photos? Submit your photos here. ›

The takeaway

Intellia's inducement grants demonstrate the company's commitment to building a talented workforce as it continues to advance its pipeline of CRISPR-based therapies. The grants, made outside of its stockholder-approved plans, highlight the company's ability to attract top talent in the competitive biopharmaceutical industry.